feed,title,long_url,short_url
SeekingAlpha,Travere Therapeutics expects Q4 net product sales from continuing operations to be about $40M,https://seekingalpha.com/news/4053139,
SeekingAlpha,Nuvalent announces 'OnTarget 2026' operating plan; aims for first approved product in 2026,https://seekingalpha.com/news/4053138,
